Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia
Access Status
Open access
Authors
Cruickshank, Mark N
Hughes, Anastasia M
Singh, Sajla
Chua, Grace-Alyssa
Ford, Jette
Ferrari, Emanuela
Oommen, Joyce
Malinge, Sébastien
Lock, Richard B
Kees, Ursula R
Kotecha, Rishi S
Date
2019Type
Journal Article
Metadata
Show full item recordCitation
Cheung, L.C. and Cruickshank, M.N. and Hughes, A.M. and Singh, S. and Chua, G.-A. and Ford, J. and Ferrari, E. et al. 2019. Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. Haematologica. 104: pp. e300-e303.
Source Title
Haematologica
ISSN
Faculty
Faculty of Health Sciences
School
School of Pharmacy and Biomedical Sciences